Evidence map›Paper›PMID 30034224›Full record

ArticleDrug design, development and therapy2018

Emodin mitigates podocytes apoptosis induced by endoplasmic reticulum stress through the inhibition of the PERK pathway in diabetic nephropathy.

Nianxiu Tian, Yanbin Gao, Xiaolei Wang, Xiaoming Wu, Dawei Zou, Zhiyao Zhu, ZheJi Han, Tao Wang, Yimin Shi

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 85 citations in OpenAlex.

  1. Post‑translational modifications in diabetic kidney disease (Review).International journal of molecular medicine · 2026
    Review
  2. Review
  3. Nanoparticles in the Treatment of Renal Fibrosis.International journal of nanomedicine · 2026
    Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Anthraquinones fromDrug design, development and therapy · 2025
    Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Acta pharmaceutica Sinica. B · 2024
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Nianxiu TianDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Fengtai District, Beijing, China, dfyynfm@163.com.
Yanbin GaoDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Fengtai District, Beijing, China, dfyynfm@163.com.
Xiaolei WangDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Fengtai District, Beijing, China, dfyynfm@163.com.
Xiaoming WuDepartment of Paediatrics, Beijing Children's Hospital, Capital Medical University, Xicheng District, Beijing, China.
Dawei ZouDepartment of Endocrinology, Beijing Key Lab of TCM Collateral Disease theory Research, Fengtai District, Beijing, China.
Zhiyao ZhuDepartment of Endocrinology, Beijing Key Lab of TCM Collateral Disease theory Research, Fengtai District, Beijing, China.
ZheJi HanDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Fengtai District, Beijing, China, dfyynfm@163.com.
Tao WangDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Fengtai District, Beijing, China, dfyynfm@163.com.
Yimin ShiDepartment of Endocrinology, School of Traditional Chinese Medicine, Capital Medical University, Fengtai District, Beijing, China, dfyynfm@163.com.
Beijing Hospital of Traditional Chinese Medicine · CNBeijing Fengtai Hospital · CNBeijing Children’s Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEndoplasmic reticulum stress is associated with podocyte apoptosis in the pathogenesis of diabetic nephropathy (DN). A previous study has demonstrated that emodin has a protective effect in the kidney by suppressing proliferation of mesangial cells and inhibiting the renal tubular epithelial-to-mesenchymal transition. However, the effects of emodin on the podocyte apoptosis in DN and its mechanisms are unknown.

aimThis study aimed to explore the effect of emodin on DN model KK-Ay mice and high glucose induced podocytes apoptosis via the PERK-eIF2α pathway.

methodsKK-Ay mice model of DN were treated with emodin at dose of 40 and 80 mg/kg/day for 8 weeks. Urine albumin, serum creatinine, blood urea nitrogen levels and the renal histopathology in mice were performed. In vitro, conditionally immortalized mouse podocytes exposed to HG (30mM) were incubated with emodin. Cell viability was measured by CCK-8 assay. Additionally, we performed RNA interference and measured the apoptosis in cultured podocytes treated with emodin. Immunohistochemistry, immunofluorescence, western blot, and real-time PCR were used to detect gene and protein expression both in vivo and in vitro.

resultsThe results showed that emodin treatment ameliorated urine albumin, serum creatinine, and blood urea nitrogen of DN mice. The pathological damage of kidney tissue was also improved after treatment with emodin. Moreover, emodin increased nephrin expression. Podocytes apoptosis and endoplasmic reticulum stress markers (GRP78) were significantly reduced upon emodin treatment. Furthermore, emodin treatment decreased the expression of phosphorylated protein kinase RNA-like endoplasmic reticulum kinase (P-PERK), phosphorylated P-eIF2α, ATF4, and CHOP. In vitro, emodin treatment was further found to decrease the GRP78 level induced by high glucose or tunicamycin (TM). Besides, emodin and PERK knockdown inhibited the apoptosis of podocytes cultured in high glucose by counteracting the upregulation of phosphorylated PERK, phosphorylated eIF2α, ATF4, and CHOP.

conclusionOverall, the findings indicate that emodin mitigates podocytes apoptosis by inhibiting the PERK-eIF2α signaling pathway in vivo and in vitro, and, therefore, exerts a protective action on podocytes in DN.

Indexed as

AnimalsApoptosisCell ProliferationCells, CulturedDiabetic NephropathiesDose-Response Relationship, DrugeIF-2 KinaseEmodinEndoplasmic Reticulum Chaperone BiPEndoplasmic Reticulum StressEpithelial-Mesenchymal TransitionMaleMiceMice, Inbred StrainsMolecular StructurePodocyteseIF-2 KinaseEmodinEndoplasmic Reticulum Chaperone BiPHspa5 protein, mouseProtein Kinasesdiabetic nephropathyemodinendoplasmic reticulum stressPERK-eIF2αpodocyte apoptosis

Identifiers

PMID30034224
PMCPMC6047613
OpenAlexW2837014476

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.